GlassScriptPhysician profile
Christopher L Shanklin
NPI 1154513182
$6,372.56
in general payments reported to CMS, 2019-2025
48 companies · $1,323 in 2025
The $1,323 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $813 · 2020: $672 · 2021: $799 · 2022: $983 · 2023: $913 · 2024: $870 · 2025: $1,323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,104.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $817.21 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $809.87 | 2021-2025 | Botox |
| Amgen INC. | $726.87 | 2019-2025 | Tavneos, Repatha, Otezla |
| Lilly USA, LLC | $571.21 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $357.47 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $326.98 | 2019-2025 | Synjardy, Jardiance, Glyxambi |
| Astrazeneca Pharmaceuticals LP | $265.58 | 2019-2025 | Farxiga, Airsupra |
| Allergan, INC. | $250.77 | 2019-2022 | |
| Harmony Biosciences LLC | $206.19 | 2022-2023 | Wakix |
| Glaxosmithkline, LLC. | $193.20 | 2019-2023 | Trelegy Ellipta |
| Biogen, INC. | $193.11 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $159.76 | 2019-2023 | Trintellix |
| Medtronic, INC. | $136.49 | 2025 | Stealthstation S8 Platform |
| Biohaven Pharmaceutical Holding Company LTD. | $122.80 | 2022 | |
| Astellas Pharma US INC | $98.83 | 2019-2024 | Veozah |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Shanklin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.